917022-13-0 Usage
Uses
Used in Pharmaceutical Industry:
Peginterferon beta-1a is used as a therapeutic agent for the treatment of multiple sclerosis (MS). It functions by impeding virus activity and assisting the immune system in curbing inflammation, which in turn slows the progression of the disease and diminishes the frequency of relapses in MS patients.
Used in Medical Treatments:
Peginterferon beta-1a is utilized as a medication to manage the symptoms and progression of multiple sclerosis. Its application is aimed at improving the quality of life for patients by reducing the severity and frequency of MS-related symptoms.
Check Digit Verification of cas no
The CAS Registry Mumber 917022-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,7,0,2 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 917022-13:
(8*9)+(7*1)+(6*7)+(5*0)+(4*2)+(3*2)+(2*1)+(1*3)=140
140 % 10 = 0
So 917022-13-0 is a valid CAS Registry Number.
InChI:InChI=1/C31H53ClN6O4/c1-30(2,3)41-28(39)37(17-10-18-38(24-11-8-7-9-12-24)29(40)42-31(4,5)6)21-23-15-13-22(14-16-23)20-34-27-35-25(32)19-26(33)36-27/h19,22-24H,7-18,20-21H2,1-6H3,(H3,33,34,35,36)/t22-,23-
917022-13-0Relevant academic research and scientific papers
MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS
-
, (2016/04/26)
A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification
LYOPHILIZATION FORMULATION
-
Page/Page column 10, (2010/06/11)
This invention relates to a pharmaceutical kit containing a lyophilized preparation of a pyrimidine compound described in the specification. Also disclosed is a lyophilization process for making this preparation.
Pyrimidine compounds
-
Page/Page column 114-115, (2008/06/13)
This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.
